Increased natural killer cells and decreased CD3+CD8+CD62L+ T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib

Curing CML with imatinib—a dream come true?

(2011) Michael Deininger   Nature Reviews Clinical Oncology

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy

(2010) Peter Rohon et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Insights into the stem cells of chronic myeloid leukemia

(2010) I Sloma et al.   LEUKEMIA

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

(2010) D M Ross et al.   LEUKEMIA

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

(2009) S Mustjoki et al.   LEUKEMIA

CD8+ memory T cells predominate over naïve T cells in therapy-free CML patients with sustained major molecular response

(2009) Kensuke Usuki et al.   LEUKEMIA RESEARCH